We are live on ! Find out more
E

Ergoteles Portfolio holdings

AUM $68.2M
1-Year Est. Return 36.16%
This Fund
S&P 500
This Quarter Est. Return
+13.32%
1 Year Est. Return
+36.16%
3 Year Est. Return
+76.43%
5 Year Est. Return
10 Year Est. Return
AUM
$2.72B
AUM Growth
-$123M
Cap. Flow
-$215M
Cap. Flow %
-7.9%
Top 10 Hldgs %
16.65%
Holding
2,200
New
704
Increased
294
Reduced
353
Closed
800

Sector Composition

Rank Sector Weight
1 Financials 15.28%
2 Healthcare 12.35%
3 Industrials 12.24%
4 Technology 10.34%
5 Consumer Discretionary 10.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BGMS
1351
Bio Green Med Solution Inc
BGMS
$4.97M
$17.3K ﹤0.01%
+7
New +$25.8K
AVGR
1352
DELISTED
Avinger, Inc. Common Stock
AVGR
$17.1K ﹤0.01%
+1,056
New +$18K
MTEM
1353
DELISTED
Molecular Templates, Inc.
MTEM
$17.1K ﹤0.01%
3,473
-7,161
-67% -$59.3K
GOEV
1354
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$16.1K ﹤0.01%
+28
New +$17.2K
SGTX
1355
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$15.3K ﹤0.01%
3,374
-1,486
-31% -$8.48K
IVVD icon
1356
Invivyd
IVVD
$177M
$15K ﹤0.01%
+10,006
New +$27.8K
SERA icon
1357
Sera Prognostics
SERA
$79.5M
$14.8K ﹤0.01%
+12,018
New +$17K
MBIO icon
1358
Mustang Bio
MBIO
$4.78M
$14.2K ﹤0.01%
48
-337
-88% -$115K
AEMD icon
1359
Aethlon Medical
AEMD
$1.48M
$13.9K ﹤0.01%
+63
New +$23K
ORBS
1360
Eightco Holdings
ORBS
$230M
$13.8K ﹤0.01%
+289
New +$32.8K
BLPH
1361
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$13.4K ﹤0.01%
+14,891
New +$15.2K
ALZN icon
1362
Alzamend Neuro
ALZN
$5.1M
$13.3K ﹤0.01%
+17
New +$24.6K
BLCM
1363
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$13K ﹤0.01%
+18,105
New +$17.9K
RKDA icon
1364
Arcadia Biosciences
RKDA
$1.42M
$12.6K ﹤0.01%
+1,163
New +$16.6K
ONCT
1365
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$12.4K ﹤0.01%
621
-4,409
-88% -$87.8K
NGNE icon
1366
Neurogene
NGNE
$669M
$12.2K ﹤0.01%
1,202
-6,364
-84% -$65.7K
ASPU
1367
DELISTED
ASPEN GROUP, INC.
ASPU
$11.8K ﹤0.01%
+37,988
New +$13.8K
AMTI
1368
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$10.7K ﹤0.01%
25,372
-78,175
-75% -$78.7K
LGMK
1369
DELISTED
LogicMark
LGMK
$10.6K ﹤0.01%
+47
New +$16.6K
LMFA
1370
DELISTED
LM Funding America
LMFA
$10.3K ﹤0.01%
+125
New +$14.9K
PLXP
1371
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$9.97K ﹤0.01%
+60,771
New +$25.4K
RUBY
1372
DELISTED
Rubius Therapeutics, Inc
RUBY
$9.94K ﹤0.01%
+57,747
New +$15.8K
DNTH icon
1373
Dianthus Therapeutics
DNTH
$5.62B
$8.61K ﹤0.01%
1,363
-5,832
-81% -$103K
VRPX
1374
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$7.89K ﹤0.01%
+51
New +$11.6K
GNLN icon
1375
Greenlane Holdings
GNLN
$1.11M
0

Similar funds

Ergoteles's Q4 2022 Portfolio in Review

As of Q4 2022, Ergoteles held 2,200 positions worth $2.72B, down 4.3% from $2.85B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Ergoteles withdrew a net $215M in Q4 2022, closing 800 positions and reducing 353 holdings. Its most notable exit was Citrix Systems Inc, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Ergoteles opened a new position in McKesson worth $43.9M.

  • Ergoteles's largest Q4 2022 buy was McKesson: 117,079 shares worth $43.9M.
  • Ergoteles added most to iShares Biotechnology ETF in Q4 2022, an estimated $85.8M increase.
  • Ergoteles's biggest Q4 2022 reduction was Alphabet (Google) Class C, cutting an estimated $41.8M.
  • Ergoteles fully exited Citrix Systems Inc in Q4 2022, selling an estimated $149M.
  • Ergoteles's ten largest holdings make up 17% of its $2.72B portfolio in Q4 2022.
  • Ergoteles opened 704 new positions and closed 800 in Q4 2022.
  • Ergoteles's portfolio value fell 4.3% quarter-over-quarter to $2.72B.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.